Skip to content

Study · Non-randomized trial · n = 58 · 2008

1 result

[Bioregulating therapy and life quality in aged patients with hypertonic angioretinopathy].

Trofimova SV, Atakhanova LE, Akhmedova EP

Advances in gerontology = Uspekhi gerontologii1 Jan 2008

PMID19432215 (opens in a new tab)PepBankPUB-19432215

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In aged patients with hypertonic angioretinopathy, visual discomfort disappeared or lessened and emotional condition improved in 61% with cortexin versus 36% with Actovegin.

    In plain wordsIn aged patients with hypertonic angioretinopathy, visual discomfort disappeared or lessened and emotional condition improved in 61% with cortexin versus 36% with Actovegin.

    Outcome
    IncreaseVisual discomfort and emotional condition response
    Study

    n = 58

    Comparator
    Actovegin added to hypotensive therapy
    Outcome group
    Vision and retina · Eye
    Studied dose
    Dose not stated

    Measurements

    Combined visual discomfort and emotional response
    61%
    cortexin group
    Combined visual discomfort and emotional response
    36%
    Actovegin group

    Source sentences

    Summary
    As a result of treatment disappearance or reduction of visual discomfort and improvement of the emotional condition of 61% of patients of the basic group and 36% of patients of control group were marked.
    1 context sentence
    Summary · context
    The studying of the comparative analysis of change of LQ and visual functions of aged patients with hypertonic angioretinopathy under adding to complex hypotensive therapies the Cortexin (the basic group, 28 people) and Actovegin (control group, 30 people) was held.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.